The success of any pre-clinical research program relies on selecting the right animal for a study, writes Emmanuel Gomas, European services manager at Envigo, in an expert view piece.
But the timing and availability of an animal research colony represents a major challenge for researchers and facility managers alike. Researchers must ensure they can rapidly expand or contract their colony and generate the appropriate number of study cohorts.
Consequently, effective colony development and cohort supply strategies are needed to enable access to a reliable and flexible supply of models, and to keep experimental programs on track.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze